Kyntra Bio
KYNB
32 hedge funds and large institutions have $13.9M invested in Kyntra Bio in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
413% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $601K
147% more capital invested
Capital invested by funds: $5.62M → $13.9M (+$8.25M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
26.95% more ownership
Funds ownership: 1.05% → 28% (+27%)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
7% more funds holding
Funds holding: 30 → 32 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$394K |
| 2 |
Two Sigma Investments
New York
|
+$245K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$221K |
| 4 |
Renaissance Technologies
New York
|
+$170K |
| 5 |
Squarepoint
New York
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$289K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$271K |
| 3 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$79.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$24.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15.2K |
KYNB Hedge Fund Activity: Q3 2025 in Review
32 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2025, worth a combined $13.9M — up 147% from $5.62M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KYNB positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, adding an estimated $394K. The largest seller was Primecap Management, cutting an estimated $289K.
- 32 institutional investors held Kyntra Bio (KYNB) as of Q3 2025, up from 30 in Q2 2025.
- Funds reported $13.9M of Kyntra Bio stock for Q3 2025, up 147% quarter-over-quarter.
- 4 funds opened new Kyntra Bio positions in Q3 2025 and 2 closed out, a net change of +2 holders.
- The largest Kyntra Bio buyer in Q3 2025 was Armistice Capital, an estimated $394K added.
- The largest Kyntra Bio seller in Q3 2025 was Primecap Management, an estimated $289K sold.
Based on aggregated 13F filings for Q3 2025.